[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339113-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-339113-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","comprehensive-analysis-of-fibroblast-activation-protein-expression-across-23-tumor-indications-insights-for-biomarker-development-in-cancer-immunotherapies","Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications - insights for biomarker development in cancer immunotherapies","","Fibroblast activation protein (FAP) is strongly induced in many tumor microenvironments and rarely detected in normal tissues. This study evaluates FAP across 1,216 tissue samples spanning 23 tumor types and 70 subtypes, integrating immunohistochemistry and RNA sequencing to link FAP gene and protein expression. Clinical relevance is assessed in 29 cohorts from 12 trials, including atezolizumab monotherapy and combination regimens with chemotherapy, where higher FAP often associates with poorer prognosis yet shows cohort-dependent survival effects. Results support FAP as a biomarker candidate for cancer immunotherapies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-analysis-of-fibroblast-activation-protein-expression-across-23-tumor-indications-insights-for-biomarker-development-in-cancer-immunotherapies/339113/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-analysis-of-fibroblast-activation-protein-expression-across-23-tumor-indications-insights-for-biomarker-development-in-cancer-immunotherapies/339113.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of analyzing fibroblast activation protein (FAP) in this study?","Question",{"text":63,"@type":64},"To characterize FAP expression across multiple tumor types and determine how FAP gene and protein levels relate to clinical outcomes and therapy response in cancer immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was FAP expression measured across the tumor samples?",{"text":68,"@type":64},"FAP was assessed using immunohistochemistry and RNA sequencing, enabling evaluation of correspondence between FAP mRNA and protein expression.",{"name":70,"@type":61,"acceptedAnswer":71},"How does FAP expression relate to patient prognosis in immunotherapy trials?",{"text":72,"@type":64},"Higher FAP expression trends toward worse prognosis, particularly in RCC, although cohort-specific patterns occur, including improved survival in some cohorts and no detectable survival impact in others.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},339113,1790147891,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Original Research PUBLISHED 15 March 2024  \nDOI 10.3389/fimmu.2024.1352615  \nOPEN ACCESS  \nEDITED BY  \nArumugam Jayakumar,  \nUniversity of Texas MD Anderson Cancer Center, United States  \nREVIEWED BY  \nWenqing Zhang,  \nSThe Ohio State University, United States Gargi Bagchi,  \nAmity University Haryana, India  \n*CORRESPONDENCE Sebastian Dziadek  \n [sebastian.dziadek@roche.com](sebastian.dziadek@roche.com)  \nRECEIVED 08 December 2023  \nACCEPTED 25 January 2024  \nPUBLISHED 15 March 2024  \nCITATION  \nDziadek S, Kraxner A, Cheng W-Y, Ou Yang T-H, Flores M, Theiss N, Tsao T-S, Andersson E, Harring SV, Bröske A-ME, Ceppi M, Teichgräber V and Charo J (2024) Comprehensive analysis of ﬁbroblast activation protein expression across  \n23 tumor indications: insights for biomarker development in cancer immunotherapies. Front. Immunol. 15:1352615 .  \ndoi: 10.3389/fimmu.2024.1352615  \nCOPYRIGHT  \n© 2024 Dziadek, Kraxner, Cheng, Ou Yang, Flores, Theiss, Tsao, Andersson, Harring, Bröske, Ceppi, Teichgräber and Charo. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nComprehensive analysis of ﬁbroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies  \nSebastian Dziadek 1*, Anton Kraxner 1, Wei-Yi Cheng 2, Tai-Hsien Ou Yang 2, Mike Flores 3, Noah Theiss 3,  \nTsu-Shuen Tsao 3, Emilia Andersson 4, Suzana Vega Harring 4, Ann-Marie E. Bröske 4, Maurizio Ceppi 1, Volker Teichgräber 1 and Jehad Charo 5  \n1 Roche Pharma Research and Early Development, Oncology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland, 2 Roche Pharma Research and Early Development, Data and Analytics, Roche Translational & Clinical Research Center, F. Hoffmann-La Roche Ltd, Little Falls, NJ, United States, 3 Roche Tissue Diagnostics, Tucson, AZ, United States, 4 Roche Pharma Research and Early Development, Oncology, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany, 5 Roche Pharma Research and Early Development, Oncology, Roche Innovation Center Zurich, Roche Glycart AG, Schlieren, Switzerland  \nIntroduction: Fibroblast activation protein (FAP) is predominantly upregulated in various tumor microenvironments and scarcely expressed in normal tissues.  \nMethods: We analyzed FAP across 1216 tissue samples covering 23 tumor types and 70 subtypes.  \nResults: Elevated FAP levels were notable in breast, pancreatic, esophageal, and lung cancers. Using immunohistochemistry and RNAseq, a correlation between FAP gene and protein expression was found. Evaluating FAP ’ s clinical signiﬁcance, we assessed 29 cohorts from 12 clinical trials, including both mono and combination therapies with the PD-L1 inhibitor atezolizumab and chemotherapy. A trend links higher FAP expression to poorer prognosis, particularly in RCC, across both treatment arms . However, four cohorts showed improved survival with high FAP, while in four others, FAP had no apparent survival impact.  \nConclusions: Our results emphasize FAP’s multifaceted role in therapy response, suggesting its potential as a cancer immunotherapy biomarker.  \nKEYWORDS  \nﬁbroblast activation protein, immunohistochemistry, mRNA expression, immunotherapy, clinical outcomes  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIntroduction  \nRecent breakthroughs in cancer immunotherapy, especially the adoption of anti-PD-1/PD-L1 treatments for multiple cancers, have transformed cancer care. The tumor microenvironment (TME) – a multifaceted network of non-malignant cells surrounding tumors – is crucial in determining cl","cbCaipbWyGVxU3yX","https://ap.wps.com/l/cbCaipbWyGVxU3yX","pdf",1458181,"English","# Introduction\n## Materials and methods\n## Patients and samples\n## Results\n## Conclusions","[{\"question\":\"What is the main purpose of analyzing fibroblast activation protein (FAP) in this study?\",\"answer\":\"To characterize FAP expression across multiple tumor types and determine how FAP gene and protein levels relate to clinical outcomes and therapy response in cancer immunotherapy.\"},{\"question\":\"How was FAP expression measured across the tumor samples?\",\"answer\":\"FAP was assessed using immunohistochemistry and RNA sequencing, enabling evaluation of correspondence between FAP mRNA and protein expression.\"},{\"question\":\"How does FAP expression relate to patient prognosis in immunotherapy trials?\",\"answer\":\"Higher FAP expression trends toward worse prognosis, particularly in RCC, although cohort-specific patterns occur, including improved survival in some cohorts and no detectable survival impact in others.\"}]","Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications - insights for biomarker development in cancer immunotherapies | PDF",1790027979,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b4397262f4bcf744f127d0f86739a63.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/063f1b21637b0f4264a0fe75df8cfcd9.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a53beb36b4bfa18b81c2c14f039c4e7.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/879a0a8ffc544290f761495de228e19c.webp",980,1385]